Research Explainer
Do you have to take a GLP-1 medicine forever?
There’s no single answer for everyone. Here is how current guidance and research frame long-term use—and where the evidence is still thin.
How WHO frames it
WHO’s 2025 guideline describes obesity as a chronic, relapsing disease that can be treated with comprehensive and lifelong care. It says GLP-1 therapies may be used by adults, excluding pregnant women, for long-term treatment—as part of an approach that includes healthy diets, physical activity, and professional support.[1]
What happened when treatment stopped
In the STEP 4 trial, people who continued semaglutide from week 20 to week 68 had an estimated average body-weight change of −7.9%; those switched to placebo had +6.9%.[2]
Medicine is one part
“While medication alone won’t solve this global health crisis, GLP-1 therapies can help millions overcome obesity and reduce its associated harms,” said WHO Director-General Dr Tedros Adhanom Ghebreyesus.[1] Harvard experts also stress diet and exercise alongside GLP-1 medication.[3]
Why it’s still open
WHO made its recommendation conditional because of limited data on long-term efficacy and safety, maintenance and discontinuation, current costs, health-system preparedness, and potential equity implications.[1]
What this does not answer
It does not show that every person will have the same experience after a treatment change. Individual decisions and support needs belong with a qualified healthcare professional.
Common questions
- Is long-term use recommended?
- WHO’s recommendation for long-term use in adults is conditional, not unconditional, because long-term data are limited.[1]
- Who does WHO’s guideline exclude?
- The long-term use recommendation applies to adults and excludes pregnant women.[1]
- Does cost come into it?
- Yes. WHO lists current costs and health-system preparedness among the reasons its recommendation is conditional.[1]
This page is for general education and event programming. It does not provide medical advice, diagnose conditions, recommend treatment, or endorse a medication, provider, product, or service.
Sources
- [1]WHO issues global guideline on the use of GLP-1 medicines in treating obesityWorld Health OrganizationRead the source (opens in a new tab)
- [2]The STEP 4 Randomized Clinical TrialJAMARead the source (opens in a new tab)
- [3]Diet, exercise still important when taking weight-loss medicationHarvard T.H. Chan School of Public HealthRead the source (opens in a new tab)
